[go: up one dir, main page]

EP0407399A4 - Immunosupression with anti-pan t-cell immunotoxin compositions - Google Patents

Immunosupression with anti-pan t-cell immunotoxin compositions

Info

Publication number
EP0407399A4
EP0407399A4 EP19890902585 EP89902585A EP0407399A4 EP 0407399 A4 EP0407399 A4 EP 0407399A4 EP 19890902585 EP19890902585 EP 19890902585 EP 89902585 A EP89902585 A EP 89902585A EP 0407399 A4 EP0407399 A4 EP 0407399A4
Authority
EP
European Patent Office
Prior art keywords
immunosupression
pan
cell immunotoxin
immunotoxin compositions
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890902585
Other languages
English (en)
Other versions
EP0407399A1 (fr
Inventor
Patrick J. Scannon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Royalty Corp
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corp filed Critical Xoma Corp
Publication of EP0407399A1 publication Critical patent/EP0407399A1/fr
Publication of EP0407399A4 publication Critical patent/EP0407399A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817Toxins
    • A61K47/6819Plant toxins
    • A61K47/6825Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827Ricin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Botany (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP19890902585 1988-02-03 1989-02-03 Immunosupression with anti-pan t-cell immunotoxin compositions Withdrawn EP0407399A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US151741 1980-05-20
US15174188A 1988-02-03 1988-02-03

Publications (2)

Publication Number Publication Date
EP0407399A1 EP0407399A1 (fr) 1991-01-16
EP0407399A4 true EP0407399A4 (en) 1991-06-19

Family

ID=22540067

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890902585 Withdrawn EP0407399A4 (en) 1988-02-03 1989-02-03 Immunosupression with anti-pan t-cell immunotoxin compositions

Country Status (3)

Country Link
EP (1) EP0407399A4 (fr)
JP (1) JPH03503164A (fr)
WO (1) WO1989006967A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
FI914160A7 (fi) * 1989-03-06 1991-09-03 Univ California Autoimmuunisten tautien analysointi ja hoito
US5397702A (en) * 1989-03-06 1995-03-14 The Regents Of The University Of California Assay for and treatment of autoimmune diseases
IL98932A0 (en) * 1990-07-27 1992-07-15 Univ California Assay,kits and methods based on nk+channel expression
IT1249051B (it) * 1991-02-26 1995-02-11 Italfarmaco Spa Immunotossina da anticorpi monoclonali anti-cd5
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) * 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
ATE249840T1 (de) * 1991-12-13 2003-10-15 Xoma Corp Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
EP0945139A1 (fr) * 1998-03-23 1999-09-29 Katholieke Universiteit Nijmegen Méthode et moyens de traitement de maladies immunologiques telle que la maladie des greffes vis-à-vis de l'hÔte

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
US4731244A (en) * 1985-11-13 1988-03-15 Ortho Pharmaceutical Corporation Monoclonal antibody therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents have been disclosed. *
See also references of WO8906967A1 *

Also Published As

Publication number Publication date
JPH03503164A (ja) 1991-07-18
WO1989006967A1 (fr) 1989-08-10
EP0407399A1 (fr) 1991-01-16

Similar Documents

Publication Publication Date Title
GR890100636A (en) Analgesic compositions
GB2217229B (en) Solubilising composition
IL92230A0 (en) Antibody-drug conjugates
EP0407399A4 (en) Immunosupression with anti-pan t-cell immunotoxin compositions
GB8801756D0 (en) Copolymer composition
ZA919836B (en) Gasoline composition
GB8827697D0 (en) Fabric-treatment composition
US4962144B1 (en) Composition
GB2251493B (en) Engaging lever arrangement
ZA89524B (en) Antibody conjugates
GB8827698D0 (en) Fabric-treatment composition
GB8925535D0 (en) Gasoline composition
ZA891031B (en) Compositions with enhanced penetration
GB8822967D0 (en) Moss-killing composition
GR890100837A (en) Herbicidac composition
IE883489L (en) Drug-monoclonalantibody conjugates
SG177594G (en) Gasoline composition
GB8803035D0 (en) Copolymer composition
GB8801995D0 (en) Copolymer composition
PL276880A1 (en) Antielectrostatic epoxyd composition
RO101699B1 (en) Polyolefines composition
IL92875A0 (en) Iminothiolanes and immunotoxin compositions comprising them
CS8801053A2 (en) Glow-starter with two bi-metals
IE841526L (en) Immunotoxin conjugates
GB8800647D0 (en) Composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19900723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19910426

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19920304

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19920715